Companies › Nuvalent
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Neladalkib (NVL-655) ALK inhibitor | ALK | Phase 3 | Non-small Cell Lung Cancer; Locally Advanced Solid Tumor | Dec 2027 |
| NVL-330 HER2 tyrosine kinase inhibitor | ERBB2 | Phase 1 | Locally Advanced Solid Tumor | Jan 2027 |
| Zidesamtinib (NVL-520) ROS1 inhibitor | ROS1 | Phase 1 | Locally Advanced Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06521554 | NVL-330 | Phase 1 | Locally Advanced Solid Tumor | Oncology | Jan 2027 |
| NCT05384626 | Neladalkib (NVL-655) | Phase 1 | Locally Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT05118789 | Zidesamtinib (NVL-520) | Phase 1 | Locally Advanced Solid Tumor | Oncology | Dec 2027 |
| NCT06765109 | Neladalkib (NVL-655) | Phase 3 | Non-small Cell Lung Cancer | Oncology | Dec 2029 |
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
SystImmune Shenzhen TargetRx CStone Pharmaceuticals DualityBio Aston Sci.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.